Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa

Clinical Microbiology and Infection

Volumn 10, Issue 10, 2004, Pages 877-883

  Islam, S ^a   Jalal, S ^a   Wretlind, Bengt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Amikacin; Efflux; MexZ MexX MexY; Multidrug efflux; Pseudomonas aeruginosa; Resistance

Indexed keywords

ACYLTRANSFERASE; AMIKACIN; ANTIPORTER; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; MESSENGER RNA; NETILMICIN; NORFLOXACIN; NUCLEOTIDYLTRANSFERASE; PHOSPHOTRANSFERASE; PROTEIN MEXXY; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; CYSTIC FIBROSIS; DNA SEQUENCE; GENE EXPRESSION; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATOR GENE; SEQUENCE ANALYSIS;

PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 6444222946     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00991.x     Document Type: Article

References (38)

1. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60: 539-574.
2. Li XZ, Zhang L, Poole K. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J Antimicrob Chemother 2000; 45: 433-436.
3. Nikaido H. Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin Infect Dis 1998; 27(suppl 1): S32-S41.
4. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998; 27(suppl 1): S93-S99.
5. Aires JR, Kohler T, Nikaido H, Plesiat P. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 1999; 43: 2624-2628.
6. Westbrock-Wadman S, Sherman DR, Hickey MJ et al. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother 1999; 43: 2975-2983.
7. Li XZ, Nikaido H, Poole K. Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 1948-1953.
8. Poole K, Krebes K, McNally C, Neshat S. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol 1993; 175: 7363-7372.
9. Poole K, Gotoh N, Tsujimoto H et al. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996; 21: 713-724.
10. Kohler T, Michea-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechere JC. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 1997; 23: 345-354.
11. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43: 415-417.
12. Chuanchuen R, Narasaki CT, Schweizer HP. The MexJK efflux pump of Pseudomonas aeruginosa requires OprM for antibiotic efflux but not for efflux of triclosan. J Bacteriol 2002; 184: 5036-5044.
13. Saier MH, Tam R, Reizer A, Reizer J. Two novel families of bacterial membrane proteins concerned with nodulation cell division and transport. Mol Microbiol 1994; 11: 841-847.
14. Aires JR, Pechere JC, Van Delden C, Kohler T. Amino acid residues essential for function of the MexF efflux pump protein of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 2169-2173.
15. Rosenberg EY, Ma D, Nikaido H. AcrD of Escherichia coli is an aminoglycoside efflux pump. J Bacteriol 2000; 182: 1754-1756.
16. MacLeod DL, Nelson LE, Shawar RM et al. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. J Infect Dis 2000; 181: 1180-1184.
17. Miller GH, Sabatelli FJ, Naples L, Hare RS, Shaw KJ. The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin - a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups. J Chemother 1995; 7(suppl 2): 31-44.
18. Phillips I, King A, Shannon K. Prevalence and mechanisms of aminoglycoside resistance. A ten-year study. Am J Med 1986; 80: 48-55.
19. Shimizu K, Kumada T, Hsieh WC et al. Comparison of aminoglycoside resistance patterns in Japan, Formosa, and Korea, Chile, and the United States. Antimicrob Agents Chemother 1985; 28: 282-288.
20. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Contribution of the MexX-MexY-OprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 2242-2246.
21. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, Mex-CD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 3322-3327.
22. Okamoto K, Gotoh N, Nishino T. Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 2696-2699.
23. Wolter DJ, Hanson ND, Lister PD. Multi-drug resistance associated with MexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital. Clin Microbiol Infect 2003; 9(suppl 1): 56.
24. Jalal S, Ciofu O, Høiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2000; 44: 710-712.
25. Mabilat C, Lourencao-Vital J, Goussard S, Courvalin P. A new example of physical linkage between Tn1 and Tn21: the antibiotic multiple-resistance region of plasmid pCFF04 encoding extended-spectrum beta-lactamase TEM-3. Mol Gen Genet 1992; 235: 113-121.
26. Sabtcheva S, Galimand M, Gerbaud G, Courvalin P, Lambert T. Aminoglycoside resistance gene ant(4′)-IIb of Pseudomonas aeruginosa BM4492, a clinical isolate from Bulgaria. Antimicrob Agents Chemother 2003; 47: 1584-1588.
27. Torres C, Perlin MH, Baquero F, Lerner DL, Lerner SA. High-level amikacin resistance in Pseudomonas aeruginosa associated with a 3′-phosphotransferase with high affinity for amikacin. Int J Antimicrob Agents 2000; 15: 257-263.
28. Evans K, Adewoye L, Poole K. MexR repressor of the mexAB-oprM multidrug efflux operon of Pseudomonas aeruginosa: identification of MexR binding sites in the mexA-mexR intergenic region. J Bacteriol 2001; 183: 807-812.
29. Saito K, Eda S, Maseda H, Nakae T. Molecular mechanism of MexR-mediated regulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. FEMS Microbiol Lett 2001; 195: 23-28.
30. Barbosa TM, Levy SB. Differential expression of over 60 chromosomal genes in Escherichia coli by constitutive expression of MarA. J Bacteriol 2000; 182: 3467-3474.
31. Jo JTH, Brinkman FSL, Hancock REW. Aminoglycoside efflux in Pseudomonas aeruginosa: involvement of novel outer membrane proteins. Antimicrob Agents Chemother 2003; 47: 1101-1111.
32. Li XZ, Barre N, Poole K. Influence of the MexA-MexB-OprM multidrug efflux system on expression of the MexC-MexD-OprJ and MexE-MexF-OprN multidrug efflux systems in Pseudomonas aeruginosa. J Antimicrob Chemother 2000; 46: 885-893.
33. Oliver A, Baquero F, Blazquez J. The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol 2002; 43: 1641-1650.
34. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288: 1251-1254.
35. Grinius LL, Goldberg EB. Bacterial multidrug resistance is due to a single membrane protein which functions as a drug pump. J Biol Chem 1994; 269: 29998-30004.
36. Sabath LD. Biochemical and physiologic basis for susceptibility and resistance of Pseudomonas aeruginosa to antimicrobial agents. Rev Infect Dis 1984; 6(suppl 3): S643-S656.
37. Shawar RM, MacLeod DL, Garber RL et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999; 43: 2877-2880.
38. Hurley JC, Miller GH, Smith AL. Mechanism of amikacin resistance in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Diagn Microbiol Infect Dis 1995; 22: 331-336.